Davide Liborio Vetrano: Metabolic Dysregulation as the Core Signature of Multimorbidity
Davide Liborio Vetrano, Associate Professor of Geriatric Research at Karolinska Institutet, posted on LinkedIn:
“Finally out our last study published in Nature Medicine.
Have a look here.
Title: Shared and specific blood biomarkers for multimorbidity
Authors: Alice Margherita Ornago, Caterina Gregorio, Federico Triolo, Ann Zenobia Moore, Alessandra Marengoni, Giorgi Beridze, Giulia Grande, Giuseppe Bellelli, Matilda Dale, Claudia Fredolini, Luigi Ferrucci, Laura Fratiglioni, Amaia Calderón-Larrañaga, Davide Liborio Vetrano

We investigated how a broad panel of blood biomarkers reflecting metabolic, inflammatory, vascular, renal and neurodegenerative processes relates to multimorbidity. Across multiple definitions and longitudinal analyses, metabolic dysregulation consistently emerged as the central biological signature of multimorbidity development and progression. Biomarkers such as GDF15, HbA1c, insulin, leptin and cystatin C showed robust and shared associations across multimorbidity measures, with findings validated in an independent cohort. Advanced multivariate analyses identified distinct biological subprofiles, linking shared and pattern-specific pathways to disease accumulation. Overall, our results support the geroscience hypothesis, highlighting immunometabolic stress as a key, potentially actionable mechanism underlying complex multimorbidity.

A rewarding collaboration among Karolinska Institutet, KTH Royal Institute of Technology, SciLifeLab, Università degli Studi di Milano-Bicocca, Università degli Studi di Brescia, National Institute Of Aging. My biggest acknowledgment goes to Alice Margherita Ornago and Caterina Gregorio for leading the study. Big thanks to all the collaborators for their exceptional input and work: Federico Triolo, Ann Zenobia Moore, Alessandra Marengoni, Giorgi Beridze, Giuseppe Bellelli, Giulia Grande, Matilda Dale, Claudia Fredolini, Luigi Ferrucci, Laura Fratiglioni, Amaia Calderón-Larrañaga.”
Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
Jul 12, 2026, 17:04Marc Carrier: EPCAT III Trial at ISTH 2026 Supports Aspirin Alone for VTE Prevention After Arthroplasty
-
Jul 12, 2026, 16:15Louise St. Germain Bannon: Global Collaboration Is Key to Turning Scientific Innovation Into Better Care
-
Jul 12, 2026, 16:10Marc Carrier: Major Scientific Highlight Confirms the Safety of the YEARS Algorithm at ISTH 2026
-
Jul 12, 2026, 16:01Joseph R. Shaw: Sharing New Insights into Antithrombotic Therapy and Thrombin Generation at ISTH 2026
-
Jul 12, 2026, 15:45Nathan Connell: Key Clinical Advances in Heavy Menstrual Bleeding and Postpartum Hemorrhage from ISTH 2026
-
Jul 12, 2026, 15:40Anne-Claire Duchez: Join Us at ISTH 2026 to Discover Our Latest Research and Meet the Team
-
Jul 12, 2026, 12:30Reduced-Dose DOACs in GI Malignancies: Toward Personalized Anticoagulation
-
Jul 12, 2026, 08:50Where the Hemophilia Community Comes Together at ISTH 2026 – EAHAD
-
Jul 12, 2026, 08:2210 Posts Not To Miss from ISTH 2026, Part 1